Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Hey Sloppy Joe....have you done some DD on my picks???

<< Previous

Bullboard Posts

Next >>

Comment by whateveryousayon Jul 12, 2020 2:47pm

163 Views

Post# 31257764

RE:Hey Sloppy Joe....have you done some DD on my picks???

It is still up 400% in 5 months of course some are selling with huge gains always a risk to buy at the top on news.All of the biotechs are risky fortunes are made and lost in this industry.I am in RVV and WUHN in the US may buy back into AGN this week.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing